Literature DB >> 20616161

Functional polymorphisms in matrix metalloproteinases-1, -3, -9 are associated with arteriovenous fistula patency in hemodialysis patients.

Chih-Ching Lin1, Wu-Chang Yang, Ming-Yi Chung, Pui-Ching Lee.   

Abstract

BACKGROUND AND OBJECTIVES: Matrix metalloproteinases (MMPs) are risk factors for cardiovascular diseases. This study evaluated the association of genotype polymorphisms of MMPs and tissue inhibitors of metalloproteinases (TIMPs) in hemodialysis (HD) patients with arteriovenous fistula (AVF) failure. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Genotype polymorphism of MMP-1, MMP-2, MMP-3, and MMP-9 and TIMP-1 and TIMP-2 and clinical and laboratory parameters were compared between Chinese HD patients with (n = 170) and without (n = 426) AVF failure.
RESULTS: Significant associations were found between AVF failure and the following factors (hazard ratio): longer HD duration (1.007 per month), lower pump flow (0.991 per ml/min), higher dynamic venous pressure (1.016 per mmHg), location of AVF on right side (1.630 versus left side) and upper arm (2.385 versus forearm), history of cardiovascular disease (1.656 versus absence of history), 1G/1G genotype of MMP-1 -1607 1G >2G SNP (2.315 versus 1G/2G + 2G/2G genotypes), 6A/6A genotype of MMP-3 -1612 5A >6A SNP (1.712 versus 5A/6A + 5A/5A), and C/C genotype of MMP-9 -1562 C>T SNP (1.650 versus C/T+T/T). The positive predictive rates for AVF failure were 63.0% and 6.7% for patients with the highest-risk (1G1G/6A6A/CC) and lowest-risk (2G2G or 2G1G/5A5A or 6A6A/TT or TC) composite MMP-1/MMP-3/MMP-9 genotype, respectively. The unassisted patency of AVF at 5 years decreased significantly from 93.3% to 38.4% for the composite MMP-1/MMP-3/MMP-9 genotypes (lowest versus highest risk, P < 0.001).
CONCLUSIONS: Specific genotypes of MMP-1, MMP-3 and MMP-9 with lower transcriptional activity are associated with higher frequencies of AVF failure, which may result from more accumulation of extracellular matrix, leading to AVF stenosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616161      PMCID: PMC2974381          DOI: 10.2215/CJN.01500210

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  34 in total

Review 1.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

2.  Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region.

Authors:  I A Udalova; A Richardson; A Denys; C Smith; H Ackerman; B Foxwell; D Kwiatkowski
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access.

Authors:  M F Weiss; V Scivittaro; J M Anderson
Journal:  Am J Kidney Dis       Date:  2001-05       Impact factor: 8.860

4.  Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men.

Authors:  S E Humphries; S Martin; J Cooper; G Miller
Journal:  Ann Hum Genet       Date:  2002-11       Impact factor: 1.670

5.  Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm.

Authors:  D G Peters; A Kassam; P L St Jean; H Yonas; R E Ferrell
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

6.  Manganese superoxide dismutase signals matrix metalloproteinase expression via H2O2-dependent ERK1/2 activation.

Authors:  A C Ranganathan; K K Nelson; A M Rodriguez; K H Kim; G B Tower; J L Rutter; C E Brinckerhoff; T T Huang; C J Epstein; J J Jeffrey; J A Melendez
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

7.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms.

Authors:  R Pyo; J K Lee; J M Shipley; J A Curci; D Mao; S J Ziporin; T L Ennis; S D Shapiro; R M Senior; R W Thompson
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

8.  Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease.

Authors:  Nicolas Lamblin; Christophe Bauters; Xavier Hermant; Jean-Marc Lablanche; Nicole Helbecque; Philippe Amouyel
Journal:  J Am Coll Cardiol       Date:  2002-07-03       Impact factor: 24.094

9.  Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis.

Authors:  Giorgio Ghilardi; Maria Luisa Biondi; Marco DeMonti; Olivia Turri; Emma Guagnellini; Roberto Scorza
Journal:  Stroke       Date:  2002-10       Impact factor: 7.914

10.  The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease.

Authors:  Adelheid Schwarz; Werner Haberbosch; Harald Tillmanns; Andreas Gardemann
Journal:  Dis Markers       Date:  2002       Impact factor: 3.434

View more
  12 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

Review 2.  Genetic causation of neointimal hyperplasia in hemodialysis vascular access dysfunction.

Authors:  Timmy Lee; Davinder Wadehra
Journal:  Semin Dial       Date:  2011-09-15       Impact factor: 3.455

3.  ß-Catenin is markedly induced in a murine model of an arteriovenous fistula: the effect of metalloproteinase inhibition.

Authors:  Karl A Nath; Joseph P Grande; Lu Kang; Julio P Juncos; Allan W Ackerman; Anthony J Croatt; Zvonimir S Katusic
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-29

Review 4.  Vein graft adaptation and fistula maturation in the arterial environment.

Authors:  Daniel Y Lu; Elizabeth Y Chen; Daniel J Wong; Kota Yamamoto; Clinton D Protack; Willis T Williams; Roland Assi; Michael R Hall; Nirvana Sadaghianloo; Alan Dardik
Journal:  J Surg Res       Date:  2014-01-30       Impact factor: 2.192

5.  Candidate gene analysis of arteriovenous fistula failure in hemodialysis patients.

Authors:  Jeffrey J W Verschuren; Gurbey Ocak; Friedo W Dekker; Ton J Rabelink; J Wouter Jukema; Joris I Rotmans
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-04       Impact factor: 8.237

6.  MMP-9 Deletion Attenuates Arteriovenous Fistula Neointima through Reduced Perioperative Vascular Inflammation.

Authors:  Yu-Chung Shih; Po-Yuan Chen; Tai-Ming Ko; Po-Hsun Huang; Hsu Ma; Der-Cherng Tarng
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

7.  Role of plasma matrix-metalloproteases (MMPs) and their polymorphisms (SNPs) in sepsis development and outcome in ICU patients.

Authors:  Guadalupe Martin; Víctor Asensi; A Hugo Montes; Julio Collazos; Victoria Alvarez; José A Carton; Francisco Taboada; Eulalia Valle-Garay
Journal:  Sci Rep       Date:  2014-05-16       Impact factor: 4.379

8.  Candidate Gene Analysis of Mortality in Dialysis Patients.

Authors:  Tonia C Rothuizen; Gurbey Ocak; Jeffrey J W Verschuren; Friedo W Dekker; Ton J Rabelink; J Wouter Jukema; Joris I Rotmans
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

9.  Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1.

Authors:  Hélène Choquet; Eliana Trapani; Luca Goitre; Lorenza Trabalzini; Amy Akers; Marco Fontanella; Blaine L Hart; Leslie A Morrison; Ludmila Pawlikowska; Helen Kim; Saverio Francesco Retta
Journal:  Free Radic Biol Med       Date:  2016-01-19       Impact factor: 7.376

Review 10.  Opportunities and Challenges for Genetic Studies of End-Stage Renal Disease in Canada.

Authors:  Vinusha Kalatharan; Mathieu Lemaire; Matthew B Lanktree
Journal:  Can J Kidney Health Dis       Date:  2018-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.